Ginsenoside Rg5( —— )

Catalog No. M18157 CAS No. 186763-78-0

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Ginsenoside Rg5
Note

Research use only, not for human use.
Brief Description

Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease.
Description

Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease. Ginsenoside Rg5 suppresses LPS-induced nitric oxide (NO) production and proinflammatory TNF-α secretion. Ginsenoside Rg5 can ameliorate lung inflammation possibly by inhibiting the binding of LPS to toll-like receptor (TLR)-4 on macrophages. Ginsenoside Rg5 plays a novel role as an IGF-1R agonist, promoting therapeutic angiogenesis and improving hypertension without adverse effects in the vasculature. Ginsenoside Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

IGF-1R
Research Area

Neurological Disease
Indication

——

CAS Number

186763-78-0
Formula Weight

767.01
Molecular Formula

C42H70O12
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 50 mg/mL (65.19 mM)
SMILES

CC(=CCC=C(C)C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)C
Chemical Name

——